Business Description
Nanobiotix SA
ISIN : FR0011341205
Total Employee Number:
97Compare
Compare
Traded in other countries / regions
NANO.FranceNBTX.USA0QAV.UK5NR.Germany IPO Date
2016-04-08Description
Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.55 | |||||
Equity-to-Asset | -1.25 | |||||
Debt-to-Equity | -1.13 | |||||
Debt-to-EBITDA | -7.9 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 6.36 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 43.9 | |||||
3-Year EPS without NRI Growth Rate | 36.5 | |||||
3-Year FCF Growth Rate | 12.7 | |||||
3-Year Book Growth Rate | -31 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 58 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 88.6 | |||||
9-Day RSI | 73.42 | |||||
14-Day RSI | 63.03 | |||||
3-1 Month Momentum % | 9.49 | |||||
6-1 Month Momentum % | 57.07 | |||||
12-1 Month Momentum % | 583.37 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.09 | |||||
Quick Ratio | 1.09 | |||||
Cash Ratio | 0.92 | |||||
Days Sales Outstanding | 28.53 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -11.6 | |||||
Shareholder Yield % | -1.4 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -36.49 | |||||
Net Margin % | -80.83 | |||||
EBITDA Margin % | -40.71 | |||||
FCF Margin % | -114.59 | |||||
OCF Margin % | -112.75 | |||||
ROA % | -39.86 | |||||
ROIC % | -24.41 | |||||
3-Year ROIIC % | 209.92 | |||||
ROC (Joel Greenblatt) % | -271.86 | |||||
ROCE % | -4660.82 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 55.93 | |||||
EV-to-EBIT | -133.82 | |||||
EV-to-EBITDA | -150.4 | |||||
EV-to-Revenue | 61.23 | |||||
EV-to-Forward-Revenue | 53.63 | |||||
EV-to-FCF | -53.43 | |||||
Earnings Yield (Greenblatt) % | -0.75 | |||||
FCF Yield % | -1.92 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Nanobiotix SA Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 29.643 | ||
| EPS (TTM) (€) | -0.5 | ||
| Beta | 3.4565 | ||
| 3-Year Sharpe Ratio | 1.07 | ||
| 3-Year Sortino Ratio | 2.8 | ||
| Volatility % | 116.89 | ||
| 14-Day RSI | 63.03 | ||
| 14-Day ATR (€) | 1.962126 | ||
| 20-Day SMA (€) | 31.015768 | ||
| 12-1 Month Momentum % | 583.37 | ||
| 52-Week Range (€) | 4.14 - 47.6 | ||
| Shares Outstanding (Mil) | 50.79 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Nanobiotix SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Nanobiotix SA Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-24 | In 143 days | ||
| Second quarter earnings results for 2026 | 2026-09-30 | In 88 days | ||
| General meeting for 2026 | 2026-06-09 14:00 | 30.28 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-06-02 | 32.58 (-0.37%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-04-01 08:00 | 25.85 (-4.96%) | ||
| Annual report for 2025 | 2026-03-31 | 25.85 (-4.79%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-31 | 25.85 (-4.79%) | ||
| Third quarter earnings results for 2025 | 2025-11-24 | 18.34 (+3.85%) | ||
| Jefferies London Healthcare Conference | 2025-11-17 10:00 | 18.10 (+1.00%) | ||
| Second quarter earnings results for 2025 | 2025-09-30 | 13.54 (+0.00%) |
Show
Entries
Nanobiotix SA Frequently Asked Questions
What is Nanobiotix SA(LTS:0QAV)'s stock price today?
The current price of LTS:0QAV is €34.88. The 52 week high of LTS:0QAV is €47.60 and 52 week low is €4.14.
When is next earnings date of Nanobiotix SA(LTS:0QAV)?
The next earnings date of Nanobiotix SA(LTS:0QAV) is 2026-09-30 Est..
Does Nanobiotix SA(LTS:0QAV) pay dividends? If so, how much?
Nanobiotix SA(LTS:0QAV) does not pay dividend.
Press Release
Articles on Nanobiotix SA
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers